Collateral damage of COVID-19-lockdown in Germany: decline of NSTE-ACS admissions

Abstract

Sirs: The SARS-CoV-2-Pandemic reaching Germany in March 2020 led to a nation-wide lockdown with serious restrictions on public life. Based on the experiences of the tsunami-like waves of infections in other European countries, Germany was preparing for a massive load of severe COVID-19-cases by increasing the number of intensive-care-beds and by cancelling the majority of elective medical procedures to provide as many hospital beds as possible. We conducted a retrospective review of ACS-admissions to the Heart Center Ludwigshafen, an academic tertiary heart center in Germany (using ICD-codes I20.0; I21.0, I21.1 and I21.4). We compared the period March 1st to April 21st in 2020 with the same time period in the years 2017–2019 as reference. We did the same analysis for January and February 2017–2020 to show average numbers of ACS cases over the years. During the COVID-19 lockdown in Germany in March/April 2020, we observed unchanged numbers for STEMI-admissions, but a significant 50% reduction in NSTE-ACS, in both UA and NSTEMI (Fig. 1). Similar findings were previously reported in Austria and Italy [1, 2]. Fig. 1 ACS admissions to an academic tertiary heart center before and during the shut-down for the SARS-COV-2-pandemic in Germany. Panel a: Number of treated patients with STEMI, NSTEMI and UA for the periods of January and February 2017 to 2020: Numbers are stable over 4 years. Panel b: Number of treated patients with STEMI, NSTEMI and UA for the periods of March and April (until April 21st) 2017 to 2020: Numbers of NSTEMI and UA drop by 50% in 2020. STEMI ST-elevation-myocardial-infarction, NSTEMI Non-ST-elevation-myocardial-infarction, UA unstable angina We compared patient characteristics of ACS patients during the COVID-lockdown with the same time period of the year 2019 (Table 1). We did not find any relevant differences in the patient characteristics during the COVID-lockdown as compared to the year before. The current data do not provide any indication of who of the ACS population was not admitted to the hospital during the COVID-lockdown. We provide data on troponin values of all NSTEMI patients for the two time periods in 2019 and 2020 in the table. The troponin values reported are the maximal values on the first 2 days after admission for the acute event. The median troponin values during the COVID-lockdown were slightly higher as compared to the values from 2019, but significance was not reached (Table 1). Table 1 Patient characteristics of ACS patients (STEMI, NSTEMI, UA) for the time periods March, 1 to April, 21 2019 compared to March, 1 to April, 21 2020 STEMI NSTEMI UA Time period Mar-Apr 2019 Mar-Apr 2020 p value Mar-Apr 2019 Mar-Apr 2020 p value Mar-Apr 2019 Mar-Apr 2020 p value Number of admissions (n) 49 46 n.s 95 50  < 0.001 94 48  < 0.001  Female gender 26.5% (13/49) 32.6% (15/46) 0.52 27.4% (26/95) 32.0% (16/50) 0.56 38.3% (36/94) 43.8% (21/48) 0.53  Age (years. mean ± SD) 65,9 ± 14,2 64,0 ± 13,8 0.67 70,5 ± 12,3 71,7 ± 12,1 0.58 68.8 ± 13.7 70.5 ± 10.8 0.58 CV risk factors  Art. hypertension 83.7% (41/49) 73.9% (34/46) 0.24 77.9% (74/95) 82.0% (41/50) 0.56 83.0% (78/94) 83.3% (40/48) 0.96  Diabetes mellitus 16.3% (8/49) 34.8% (16/46)  < 0.05 33.7% (32/95) 40.0% (20/50) 0.45 29.8% (28/94) 20.8% (10/48) 0.25  Hyperlipidemia 51.0% (25/49) 65.2% (30/46) 0.16 61.1% (58/95) 74.0% (37/50) 0.12 45.7% (43/94) 66.7% (32/48)  < 0.05  Smoker (current) 22.4% (11/49) 15.2% (7/46) 0.37 9.5% (9/95) 6.0% (3/50) 0.47 7.4% (7/94) 10.4% (5/48) 0.55  Comorbidities 6.1% (3/49) 2.2% (1/46) 0.34 9.5% (9/95) 6.0% (3/50) 0.47 10.6% (10/94) 12.5% (6/48) 0.74  COPD 0.0% (0/49) 2.2% (1/46) 0.30 17.9% (17/95) 14.0% (7/50) 0.55 6.4% (6/94) 4.2% (2/48) 0.59  Peripheral artery disease 2.0% (1/49) 0.0% (0/46) 0.33 1.1% (1/95) 2.0% (1/50) 0.64 0.0% (0/94) 0.0% (0/48) n.a  Prior stroke/TIA 16.3% (8/49) 13.0% (6/46) 0.65 42.1% (40/95) 36.0% (18/50) 0.48 20.2% (19/94) 18.8% (9/48) 0.84  Renal failure 6.1% (3/49) 2.2% (1/46) 0.34 9.5% (9/95) 6.0% (3/50) 0.47 10.6% (10/94) 12.5% (6/48) 0.74  Troponin I hs (ng/l)Median with interquartile range n.a n.a n.a 1179,0 (294,0; 5660,0) 1501,0 (530,0; 8788,0) 0.27 n.a n.a n.a STEMI ST-elevation-myocardial-infarction, NSTEMI Non-ST-elevation-myocardial-infarction, UA unstable angina Statistical Analysis: Continuous variables are presented as mean with standard deviation or median with interquartile range and compared with Mann–Whitney-Wilcoxon test. Categorical variables are presented as counts and percentages and compared with the Chi2-test. All tests were two-tailed and p values < 0.05 were considered statistically significant. Statistical analyses were performed with SAS statistical package, version 9.4 (SAS Institute) Possible explanations for this important observation might be system-related as well as patient-related. By concentrating on the preparation for the COVID-19-pandemic with all necessary efforts undertaken to care for the isolation and treatment of suspected or confirmed cases, established integrated care systems for other acute diseases with well-defined patient pathways might have been neglected. Besides, the lockdown isolated many patients at risk for cardiovascular events and the quarantine of patients with suspected or confirmed SARS-CoV-2-infection at home sometimes might have prevented them from contacting their doctors. The acute presentation of STEMI with severe chest-pain probably still triggers the direct transportation to the cathlabs with no changes of admissions. Due to the attention to the plethora of possible symptoms of the SARS-CoV-2-infection described in the media, some patients may have mis-interpreted their NSTE-ACS symptoms such as dyspnea and chest pain as possible COVID-19-symptoms rather than as cardiovascular symptoms. As an early invasive treatment of NSTEMI-patients is associated with an improved outcome [3, 4], we might face a higher mortality by non-treated ACS patients as a collateral damage of the COVID-19-era. We, therefore, should take care about reinforcing the already established patient pathways ensuring the access to emergency cardiology care of those patients separated from the access to hospital care for COVID-19-infections that will continue to accompany us in the future until an effective vaccine is developed, to avoid undertreatment of NSTE-ACS-patients.